- Home
- NGNE vs TVA Comparison
NGNE vs TVA Comparison
Compare NGNE & TVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- TVA
- Stock Information
- Founded
- NGNE 2003
- TVA 2024
- Country
- NGNE United States
- TVA United States
- Employees
- NGNE N/A
- TVA N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- TVA
- Sector
- NGNE Health Care
- TVA
- Exchange
- NGNE Nasdaq
- TVA Nasdaq
- Market Cap
- NGNE 325.3M
- TVA 303.4M
- IPO Year
- NGNE N/A
- TVA 2025
- Fundamental
- Price
- NGNE $22.72
- TVA $10.13
- Analyst Decision
- NGNE Strong Buy
- TVA
- Analyst Count
- NGNE 7
- TVA 0
- Target Price
- NGNE $41.86
- TVA N/A
- AVG Volume (30 Days)
- NGNE 216.3K
- TVA 105.0
- Earning Date
- NGNE 08-08-2025
- TVA 01-01-0001
- Dividend Yield
- NGNE N/A
- TVA N/A
- EPS Growth
- NGNE N/A
- TVA N/A
- EPS
- NGNE N/A
- TVA N/A
- Revenue
- NGNE $925,000.00
- TVA N/A
- Revenue This Year
- NGNE N/A
- TVA N/A
- Revenue Next Year
- NGNE N/A
- TVA N/A
- P/E Ratio
- NGNE N/A
- TVA N/A
- Revenue Growth
- NGNE N/A
- TVA N/A
- 52 Week Low
- NGNE $6.88
- TVA $9.99
- 52 Week High
- NGNE $74.49
- TVA $10.34
- Technical
- Relative Strength Index (RSI)
- NGNE 60.64
- TVA N/A
- Support Level
- NGNE $20.80
- TVA N/A
- Resistance Level
- NGNE $23.88
- TVA N/A
- Average True Range (ATR)
- NGNE 1.44
- TVA 0.00
- MACD
- NGNE 0.09
- TVA 0.00
- Stochastic Oscillator
- NGNE 72.83
- TVA 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About TVA Texas Ventures Acquisition III Corp Class A Ordinary Share
Texas Ventures Acquisition III Corp is a blank check company.